GlassScriptPhysician profile
Joseph A Cavuto
NPI 1093801128
$7,088.94
in general payments reported to CMS, 2019-2025
31 companies · $1,135 in 2025
The $1,135 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $697 · 2020: $585 · 2021: $910 · 2022: $1,174 · 2023: $1,192 · 2024: $1,395 · 2025: $1,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,702 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,702.33 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,480.55 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,109.45 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,089.69 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Glaxosmithkline, LLC. | $872.25 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $394.81 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Janssen Pharmaceuticals, INC | $284.12 | 2019-2021 | |
| Gilead Sciences, INC. | $208.76 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $158.96 | 2021-2025 | Eliquis, Camzyos |
| Otsuka America Pharmaceutical, INC. | $153.51 | 2019-2024 | Rexulti, Jynarque |
| Astellas Pharma US INC | $148.52 | 2019-2021 | |
| Abbott Laboratories | $145.06 | 2021-2023 | Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $143.37 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $142.46 | 2022-2025 | |
| Pfizer INC. | $121.76 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.07 | 2022-2024 | Caplyta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $69.33 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.97 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.77 | 2019-2022 | |
| Amgen INC. | $55.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $37.98 | 2019-2022 | |
| Qiagen, LLC | $26.73 | 2024 | |
| Lundbeck LLC | $26.62 | 2023 | Rexulti |
| Horizon Therapeutics Plc | $26.55 | 2022 | |
| Merck Sharp & Dohme LLC | $25.90 | 2019 | |
| Idorsia Pharmaceuticals US INC | $24.85 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $19.95 | 2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $19.85 | 2023 | Auvelity |
| Inspire Medical Systems, INC. | $18.84 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.41 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.96 | 2025 | Voquezna |
| Allergan, INC. | $14.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Cavuto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.